Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
Author:
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology
Link
http://link.springer.com/content/pdf/10.1007/s00702-019-02026-8.pdf
Reference43 articles.
1. Athauda D, Maclagan K, Skene SS, Foltynie T et al (2017) Exenatide (Astra-Zeneca) once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664–1675
2. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B (2006) Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 253(5):601–7
3. Barnes PJ, Drazen JM, Rennard SI, Thomson NC (eds) (2009) Asthma and COPD. In: Basic mechanisms and clinical management, 2nd edn. Academic Press
4. Brundin P, Wyse R (2015) Parkinson disease: laying the foundations for disease-modifying therapies in PD. Nat Rev Neurol 11(10):553–555
5. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde: implications for Parkinson’s disease pathogenesis. Brain Res 989(2):205–213
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Abstracts;Movement Disorders Clinical Practice;2024-02
2. Gesundheitssport Tischtennis;Sportpraxis;2024
3. Neuroprotective effect of chlorogenic acid on Parkinson's disease like symptoms through boosting the autophagy in zebrafish;European Journal of Pharmacology;2023-10
4. Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury;Parkinsonism & Related Disorders;2023-09
5. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review;Brain Sciences;2023-02-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3